Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 5/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29055923 | 0.98 | LMNA (0.56) | LMNAF2TSHRSLC6A3TDP1 | |
| SCHEMBL3822911 | 0.94 | ALDH1A1 (0.58) | LMNAF2TSHRSLC6A3TDP1 | |
| SCHEMBL28132113 | 0.92 | ALDH1A1 (0.56) | LMNAF2TSHRSLC6A3TDP1 | |
| Benzene SCHEMBL27793442 | 0.90 | LMNA (0.70) | LMNAF2TSHRSLC6A3TDP1 | |
| Hydrogen Peroxide SCHEMBL27952375 | 0.90 | LMNA (0.70) | LMNAF2TSHRSLC6A3TDP1 | |
| SCHEMBL52413 | 0.90 | LMNA (0.70) | LMNAF2TSHRSLC6A3TDP1 | |
| SCHEMBL27618276 | 0.90 | TSHR (0.50) | LMNAF2TSHRSLC6A3TDP1 | |
| Alcohol SCHEMBL4578564 | 0.90 | TSHR (0.52) | LMNAF2TSHRSLC6A3TDP1 | |
| SCHEMBL108624 | 0.89 | TSHR (0.52) | LMNAF2TSHRTP53ALDH1A1 | |
| SCHEMBL5183644 | 0.89 | ALDH1A1 (0.58) | LMNAF2TSHRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023095183-A1 | A PHARMACEUTICAL COMPOSITION AND A SOLID DOSAGE FORM THEREOF | JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (JO) | 2023-06-01 | — | — | WO | claimed |
| US-20230135608-A1 | PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYL FUMARATE AS AN ACTIVE INGREDIENT PROVIDES A SPECIFIC PHARMACOKINETIC PARAMETER | CURACLE CO., LTD. (KR) | 2023-05-04 | — | — | US | claimed |
| US-20230058942-A1 | EXTENDED RELEASE MULTIPARTICULATES OF RANOLAZINE | SUN PHARMACEUTICAL IND LTD (IN) | 2023-02-23 | — | — | US | claimed |
| CN-113645962-A | Enteric coated tablet containing dimethyl fumarate | 库拉科有限公司 | 2021-11-12 | — | — | CN | claimed |
| US-20210228488-A1 | EXTENDED RELEASE COMPOSITIONS AND PROCESS FOR PREPARATION | RUBICON RES PRIVATE LIMITED (IN) | 2021-07-29 | — | — | US | claimed |
| US-20210106537-A1 | EXTENDED RELEASE MULTIPARTICULATES OF RANOLAZINE | SUN PHARMACEUTICAL IND LTD (IN) | 2021-04-15 | — | — | US | claimed |
| US-10898444-B2 | Extended release multiparticulates of ranolazine | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2021-01-26 | — | — | US | claimed |
| WO-2020242132-A1 | ENTERIC TABLET CONTAINING DIMETHYL FUMARATE | 주식회사 큐라클 | 2020-12-03 | — | — | WO | claimed |
| EP-1898886-B1 | NOVEL SUSTAINED RELEASE DOSAGE FORM | RUBICON RES PVT LTD (IN) | 2019-09-04 | — | — | EP | claimed |
| US-20190262268-A1 | ORAL MODIFIED RELEASE FORMULATIONS | RUBICON RES PRIVATE LIMITED (IN) | 2019-08-29 | — | — | US | claimed |
| US-5874582-A | REACTING BENZOYL PHTHALIC ACID OR ESTER OR ANHYDRIDE DERIVATIVES WITH HYDROXYQUINOLINE DERIVATIVES; USEFUL FOR BULK DYEING PLASTICS; HEAT RESISTANCE, COLORFASTNESS AND WEATHERPROOFING | BAYER AKTIENGESELLSCHAFT (DE) | 1999-02-23 | — | — | US | claimed |
| CN-1197083-A | Bulk dyeing process using quinolone derivative dyes | BAYER AG (DE) | 1998-10-28 | — | — | CN | claimed |
| EP-0870752-A1 | Bulk dyeing using quinophthalone dyestuffs | BAYER AG (DE) | 1998-10-14 | — | — | EP | claimed |
| EP-0754452-A2 | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract | TANABE SEIYAKU CO., LTD. (JP) | 1997-01-22 | — | — | EP | claimed |
| EP-0122815-B1 | ENTERIC-SOLUBLE PREPARATIONS AND A PROCESS FOR THEIR PRODUCTION | SANKYO COMPANY LIMITED (JP) | 1989-10-25 | — | — | EP | claimed |
| EP-0108504-B1 | A PROCESS FOR COATING SOLID PHARMACEUTICAL PREPARATIONS AND COATED PREPARATIONS THUS OBTAINED | SANKYO COMPANY LIMITED (JP) | 1987-05-13 | — | — | EP | claimed |
| US-4661162-A | MIXTURE OF POLYMER WITH POLYANIONIC POLYMER WHICH IS SOLUBLE AT LOW PH | SANKYO COMPANY, LIMITED (JP) | 1987-04-28 | — | — | US | claimed |
| US-4497847-A | MONO AND DIESTERS OF GLYCEROL AND SATURATED CARBOXYLIC ACIDS AS PLASTICIZERS | SANKYO COMPANY, LIMITED (JP) | 1985-02-05 | — | — | US | claimed |
| EP-0122815-A1 | Enteric-soluble preparations and a process for their production | SANKYO COMPANY LIMITED (JP) | 1984-10-24 | — | — | EP | claimed |
| EP-0108504-A1 | A process for coating solid pharmaceutical preparations and coated preparations thus obtained | SANKYO COMPANY LIMITED (JP) | 1984-05-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135608-A1 | PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYL FUMARATE AS AN ACTIVE INGREDIENT PROVIDES A SPECIFIC PHARMACOKINETIC PARAMETER | SLC5A2, FH, SLC5A1 | LMNA 4052/4885F2 259/4885TSHR 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.